Osprey picks up $3.8M more for immune disease treatments
Osprey Pharmaceuticals, a drug maker focusing on inflammatory and immune disease medications, added $3.8 million to its first round of funding, bringing its total to $14.8 million, according to VentureWire. The San Francisco company says the new money was needed to see its lead drug candidate through clinical trials. It did not disclose its recent investors.
Osprey has focused its resources on a drug that could treat inflammatory kidney disease. Results from its clinical trials are expected to come in by the third quarter of next year. If they are successful, the company says it will look for more capital or partnerships with other pharmaceutical companies.
Osprey raised the first $11 million in the round last May from Burrill & Co., BDC Venture Capital, GeneChem Therapeutics Venture Fund, Novo Nordisk Biotech Fund, Western Technology Seed Investment Fund and Yasuda Enterprise Development.
Next Story: How the web was won: Google’s five features to build killer web apps
Previous Story: Zensify for iPhone visualizes your personal trending topics
About the Author, Camille Ricketts
Camille is the lead writer for GreenBeat. She came to VentureBeat from Google where she worked on its traditional platforms team, particularly in TV. Before that, she was a reporter for the Wall Street Journal in New York and London. Follow her on Twitter at @camillericketts, and follow VentureBeat on Twitter at @venturebeat.
With GreenBeat 2009, VentureBeat's all-star conference on all things Smart Grid, coming up in November, Camille will be expanding coverage of this exciting space. Stay up to date by following @greenbeat2009 on Twitter or by becoming a fan of the event on Facebook here.